Given the strong evidence for central oxytocin neurocircuitry disruption in both MAGEL2 knockout mice and humans with PWS, oxytocin has been investigated as a therapeutic tool to reduce the hyperphagia and obesity associated with PWS, as well as improve the additional social, behavioral, and cognitive abnormalities that characterize this syndrome [257]. The gene discussed is OXT; the disease is obesity disorder.